Advertisement
News
Advertisement

Alliqua Initiates Life-Cycle Management Plan to Expand Wound Care Portfolio for Use in Broader Wound Indications

Fri, 03/22/2013 - 7:09am
Bio-Medicine.Org

NEW YORK, March 22, 2013 /PRNewswire/ -- Alliqua, Inc. (OTCQB:ALQA) ("Alliqua" or the "Company") today announced the initiation of a life-cycle management plan as the first phase in their portfolio expansion initiative. As part of this plan, Alliqua is making a number of product changes designed to increase adoption of SilverSeal® and Hydress® dressings. Alliqua intends that these ongoing planned modifications will address the needs of patients with a broader range of wounds as well as the specific needs of their various clinical customers. Customers should expect to see the first of these updated dressings in May 2013.

"We believe that these changes and the expansion of our dressing portfolio will increase the overall number of patients who can benefit from our technology. Feedback from our customers and a market survey we conducted suggests these changes are important considerations for physicians and patients when selecting a hydrogel dressing," said David Johnson, Alliqua's chief executive officer. "Our life-cycle management initiatives are designed to ensure our SilverSeal® and Hydress® products provide compelling solutions for our customers."

The Company expects to file a 510(k) application with the FDA for clearance of SilverSeal® incorporating additional modifications by mid 2013, after which a decision from the FDA may be forthcoming as early as the end of the year.

About Alliqua, Inc.  
Alliqua, Inc. (ALQA) ("Alliqua") is a biopharmaceutical company focused on the development, manufacturing, and distribution of proprietary transdermal wound care and drug delivery technologies.
'/>"/>

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading